Market Cap (In USD)
15.23 Million
Revenue (In USD)
2.46 Million
Net Income (In USD)
-5.62 Million
Avg. Volume
-
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.0018-0.5
- PE
- -
- EPS
- -
- Beta Value
- 1.258
- ISIN
- AU000000IVX4
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Mr. Thian Chew
- Employee Count
- -
- Website
- https://www.inviongroup.com
- Ipo Date
- 2013-05-17
- Details
- Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
More Stocks
-
OPTIMAOptima bank S.A.
OPTIMA
-
OKDBVOriola Oyj
OKDBV
-
XELXcel Energy Inc.
XEL
-
RTRFFRumble Resources Limited
RTRFF
-
STAA
-
EMIL
-
ECH
-
2100